TAP-inhibitors from old world primate 1-herpesviruses and their use: WO2009008713.
Abstract
Cytotoxic T lymphocytes (CTLs) recognize peptide antigens in the context of major histocompatibility complex (MHC) class I molecules. CTL-mediated immunity is important for defense against cancers and virus infections, and thus viruses and tumors have evolved CTL-evasion mechanisms. The transporter associated with antigen processing (TAP) is a key factor for MHC class I assembly, and TAP is a frequent target of immune evasion by viruses and tumors. WO2009008713 discloses potential therapeutic uses of TAP inhibitors encoded by Epstein-Barr virus and its lymphocryptovirus (LCV) homologs. In particular, WO2009008713 proposes the use of LCV TAP inhibitors and their combinations with other viral TAP inhibitors to elicit novel categories of CTLs that destroy target cells in which the function of TAP or other components of the MHC class I assembly pathway is inhibited. Alternatively, WO2009008713 proposes the use of LCV TAP inhibitors and their combinations with other viral TAP inhibitors to more efficiently generate tumor-specific T-cell epitopes for immunotherapy. The methods described in WO2009008713 offer the promise of new strategies of cancer immunotherapy. However, significant optimization of therapy conditions and characteriza...Continue Reading
References
The varicellovirus-encoded TAP inhibitor UL49.5 regulates the presentation of CTL epitopes by Qa-1b1
Citations
Related Concepts
Related Feeds
Antigenic Modulation
Antigenic modulation occurs when an antibody cross-links antigens on a cell surface, causing the antigens to become internalized. This can lead to therapeutic failure of monoclonal antibodies as the expression of the antigen becomes decreased on target cells. Find the latest research on antigenic modulation here.